MedTrace Logo

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

NCT02584244 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-01-16

No results posted yet for this study

Summary

The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.

Conditions

Interventions

DRUG

LUM015

DEVICE

LUM 2.6 Imaging Device

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Lumicell, Inc.

    lead INDUSTRY

Principal Investigators

  • Andrew T Chan, M.D., Ph.D · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-04
Primary Completion
2026-12-31
Completion
2027-04-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02584244 on ClinicalTrials.gov